Pharmaceuticals, Biotechnology and Life Sciences
Use in the Emergency Room demonstrates BrainScope One can reduce patient radiation exposure, decrease use of hospital resources, and shorten…
DUBLIN–(BUSINESS WIRE)–The “5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2019” drug…
DUBLIN–(BUSINESS WIRE)–The “5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2019” drug…
DUBLIN–(BUSINESS WIRE)–The “Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019” drug pipelines…
DUBLIN–(BUSINESS WIRE)–The “Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019” drug pipelines…
DUBLIN–(BUSINESS WIRE)–The “Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. This…
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
GenSIght will present results from the REVERSE Phase III clinical trial of GS010 at the 2019 American Academy of Neurology (AAN) Annual Meeting
59 percent complete response rate in a subset of patients withendoscopically unresectable low-grade upper tract urothelial cancer(UTUC).
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,announced that on May 3, 2019 the Compensation Committee of Puma’s Boardof Directors approved the grant of inducement restricted stock unitawards covering an aggregate of 49,125 shares of Puma common stock tonine new non-executive employees.